Diagnos Announces Upsize of Previously Announced Brokered Private Placement to $3.65M Led by Centurion One Capital

Executive Summary

• Diagnos Inc. upsized its brokered private placement to up to 12,166,667 units at $0.30 per unit, targeting gross proceeds of approximately $3.65 million.
• Each unit includes one common share and one common‑share purchase warrant (exercise price $0.40, 18‑month term). An additional option for the lead agent allows up to 1,750,000 extra units (~$525,000) if needed.
• Proceeds will be used for regulatory affairs, product development, business development and general corporate purposes; closing expected around December 3, 2025.

Key Details

• Units Offered: Up to 12,166,667 (plus optional 1,750,000 additional units).
• Issue Price: $0.30 per unit.
• Aggregate Gross Proceeds: Approximately $3,650,000; potential extra $525,000 if the option is exercised.
• Unit Composition: 1 common share + 1 common‑share purchase warrant.
• Warrant Terms: Right to purchase one additional share at $0.40 per share, exercisable for 18 months after the closing date.
• Lead Agent / Bookrunner: Centurion One Capital Corp. (lead agent and sole bookrunner).
• Use of Proceeds: Regulatory affairs, product development, business development, and general corporate purposes.
• Closing Date: Expected on or about December 3, 2025 (subject to approvals, including TSX Venture Exchange).
• Holding Period: Four months and one day from the closing date under Canadian securities law.
• Insider Participation: Up to ~50% of the offering may be purchased by insiders/lead agent; expected to be exempt from MI 61‑101 valuation and minority‑shareholder approval requirements because consideration is not expected to exceed 25% of market cap.
• Geographic Offering Scope: Private placement in BC, Alberta, Ontario, Quebec, U.S. (exempt under U.S. Securities Act), and other jurisdictions as mutually agreed, without prospectus filing obligations.

Notable Quotes

(No executive quotes were provided in the release.)